On most evenings at the diabetes clinic, the conversation eventually returns to the same word: cost. Not calories, not carb counting, cost. For many patients, drugs like Ozempic hover in that uncomfortable place between medical success and financial affordability. Doctors spoke with optimism about their benefits; The patients listened, did the math, and quietly returned to the old medications, strict diets, and long walks.That equation may just change.With the patent on semaglutide (Ozempic) expiring on March 20, Indian pharmaceutical companies such as Sun PharmaZydus Lifesciences, Dr Reddy’s and Natco Pharma are preparing to launch more affordable versions of the once-exclusive injection. What was till now a premium therapy may soon become a mainstream prescription, potentially reshaping India’s rapidly growing anti-obesity and diabetes market.
Image: D.D
But apart from increasing access to affordable medicine, it also signals a change in behaviour.For years, treatment plans for obesity and type 2 diabetes in India have relied heavily on lifestyle modifications: disciplined diet, exercise regimen, and incremental pharmaceutical support when necessary. Semaglutide, known globally for its dual effects on blood sugar and weight loss, has introduced a powerful new lever. Yet its price ensured that for many it remained the last option rather than the first option.As generic drugs emerge, doctors may reconsider when to prescribe them. Patients who once had treatment delayed could start earlier. An increase may be seen in weight management clinics. And the uneasy balance between lifestyle and medicine, between personal discipline and medicinal support, can tilt in unexpected ways.The question now is not just whether semaglutide will be cheaper. The question is whether its affordability will quietly redefine the boundaries of how India treats weight, health and responsibility.
How does Ozempic work?
To understand why semaglutide has generated so much excitement and debate, it helps to start with what it actually does inside the body.After eating, our intestine releases a hormone called incretin. These chemical messengers tell the pancreas to produce insulin, which helps move sugar out of the bloodstream and into the cells where it is needed. They also signal the liver to slow down its sugar production and send a simple message to the brain: You ate enough.Ozempic works by enhancing that natural system.
.
Its active ingredient mimics a hormone called glucagon-like peptide-1 (GLP-1), which the body produces after meals. In people with type 2 diabetes, this response is often blunted. Semaglutide steps in to strengthen this. It causes the body to release insulin when blood sugar rises, reduces excess glucose from the liver, and slows the rate at which food leaves the stomach. The combined effect stabilizes blood sugar levels and improves HbA1c readings, which essentially helps in long-term glucose control.But the effect of the medicine does not stop at sugar.GLP-1 also acts on hunger centers in the brain. It indicates satiation, that subtle feeling of fullness that tells a person to put down the fork. By creating a more stable and longer-lasting version of this hormone, semaglutide enhances that feeling. This change can mean a lot for people suffering from obesity. The constant mental battle over food subsides. Weight loss tends to be less due to consistent abstinence and more due to biology working in their favor.
Low prices, wide reach – and the market is sure to boom
More players are lining up to join the fray in the coming months, and with each new entrant, pricing pressure is expected to increase. Until now, India’s weight loss medicine sector has largely been a playground of high-priced innovator brands, accessible only to a few. That exclusivity cannot last long.Industry watchers estimate the current weight loss market to be worth around Rs 1,400 crore and believe it could double within a year if prices soften and supplies increase. Both medical and consumer appetite is clearly present.The momentum isn’t limited to obesity drugs alone. The broader anti-diabetes therapy market grew more than 15% in January, driven largely by new, premium treatments, according to data from research firm Pharmarack. These include Eli Lilly’s Monzaro, which generated sales of Rs 112 crore – a sign that patients and doctors are willing to embrace innovation even at higher prices.Raman Nath of Nath Medicines said, “The patent expiry is going to have a huge impact on the market. The expiry is going to happen on the 20th and by the 21st we have got a report that 5 different semaglutides are going to be launched.”What has changed now is the equation between demand and affordability. If generic drugs significantly reduce costs, these drugs could shift from typical, urban prescriptions to more mainstream treatments. And with that shift, the conversation about weight and diabetes management in India may become less about who can access cutting-edge care — and how widely it can be used.“Doctors prescribe such medicines depending on the economic background of the patients. If they feel the patient is doing well, they will prescribe medicines like Ozempic, otherwise they will prescribe cheaper alternatives,” he said. Raman.
Beyond weight loss: the question of body image
Beyond clinics and balance sheets, another quiet debate is unfolding, a debate about the meaning of mirrors, self-worth, and acceptance.In recent months, the conversation about GLP-1 drugs like Ozempic has moved beyond blood sugar levels and BMI charts. In social media panels and televised debates, some commentators have suggested that if weight could be reduced medically, the urgency of movements focused on body acceptance would begin to wane. The implication is subtle but powerful: if body size is seen as easily changeable with an injection, then living in a larger body risks being framed as a choice rather than a complex mix of biology, environment, and circumstance.For years, the body positivity movement has argued for dignity and inclusion regardless of size. This pushed back the idea that value was measured in kilograms. But as drugs like semaglutide become more visible, and potentially more affordable, public perceptions and attitudes may change. If thinness begins to seem medically attainable, will social tolerance decrease?
These medications help control appetite and blood sugar; They don’t directly treat shame, stigma, or years of internalized criticism. Research has shown that body size and body image are closely related. Then, it’s not surprising that some people may hope that weight loss will also quiet harsh inner voices or soften the way the world reacts to them.Yet access remains unequal, outcomes vary, and no injection can fully unlock the emotional layers associated with food and appearance. As semaglutide becomes more mainstream, India may find itself poised toward not only a medical shift, but also a cultural shift that balances the promise of better health with the need to preserve empathy, dignity, and choice for bodies of every size.Raman said, “There are two types of medicines that are sold the most in this country. One for being fair and one for being slim. Ozempic helps in slimming. People rarely want to change their lifestyle. To be slim you have to make a lot of changes and be careful about how you live, what you eat. Ozempic has made it easier to lose weight, so people take it more.”
risk of abuse
Originally designed to treat type 2 diabetes, these drugs have quickly gained second identity as powerful tools for rapid weight loss. For many patients, the results seemed dramatic, even life-changing, achieving reductions that old diets, pills, and fitness fads had rarely provided. It is no wonder that he is being described as a game changer.But as his popularity increases, so do the questions.Most GLP-1 medications are taken as an injection once a week, self-administered into the arm, thigh, or abdomen. Treatment usually starts with a low dose which is gradually increased. Within a few weeks, many users notice a change: cravings subside, portions go down, the constant mental chatter about food subsides. For some people, the scale begins to rise for the first time in years.
AI generated image
Yet doctors stress that these drugs are not magic, and they are not designed to be casual lifestyle accessories. Weight often returns within a year of stopping the medication, as the body’s biological desire to regain lost weight becomes active again. Without regular exercise, especially strength training, patients may lose fat as well as muscle, a concern in a country where diets are often high in carbohydrates and low in protein.Dr Arun Mundhra, senior consultant physician, Sant Parmanand Hospital, Civil Lines, said, “It is indicated for weight loss therapy, but it should be taken only under medical guidance. There is always a possibility of misuse if the sale is not restricted.”There are other limitations too. Not everyone responds to GLP-1 therapy, and many people reach a plateau after losing about 15% of their body weight. Side effects are usually manageable, including nausea, bloating, diarrhea, but rare complications such as gallstones or pancreatitis may occur. Long-term, unsupervised use has its own risks.Dr. Mundhara also emphasized that the use of semaglutide will increase manifold once cheaper generic medicines become available.
